CD22 CAR T cells after Kymriah for B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell ALL (a type of blood cancer) that has come back or didn't respond to treatment.
- You must be between 1 and 25 years old at the time you join the study.
- Your cancer cells must have proteins called CD19 and CD22 on them (your doctor can check this).
- You should be healthy enough for treatment: your organs (kidneys, liver, heart, lungs) must work well, and your blood cell counts need to be at certain levels.
- If you've had a stem cell transplant from a donor, it must be at least 100 days ago, and you must be free of graft-versus-host disease and off immune-suppressing drugs for at least 30 days.
- If you're of childbearing age, you must agree to use birth control during treatment and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.